DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Hazard ratio

Hazard ratio

  • Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials

    Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials

  • Survival Analysis: Part I — Analysis Korean Journal of Anesthesiology of Time-To-Event

    Survival Analysis: Part I — Analysis Korean Journal of Anesthesiology of Time-To-Event

  • Delineating Virulence of Vibrio Campbellii

    Delineating Virulence of Vibrio Campbellii

  • Making Comparisons

    Making Comparisons

  • Survival Analysis Using a 5‐Step Stratified Testing and Amalgamation

    Survival Analysis Using a 5‐Step Stratified Testing and Amalgamation

  • Introduction to Survival Analysis in Practice

    Introduction to Survival Analysis in Practice

  • Research Methods & Reporting

    Research Methods & Reporting

  • University of South Florida Univers

    University of South Florida Univers

  • Meta-Analysis of Time-To-Event Data

    Meta-Analysis of Time-To-Event Data

  • Infections in Early Life and Development of Celiac Disease

    Infections in Early Life and Development of Celiac Disease

  • Subtleties in the Interpretation of Hazard Ratios

    Subtleties in the Interpretation of Hazard Ratios

  • Research Reproducibility As a Survival Analysis

    Research Reproducibility As a Survival Analysis

  • Hazard Ratio

    Hazard Ratio

  • Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?*

    Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?*

  • Multivariate and Network Meta-Analysis of Multiple Outcomes BMJ: First Published As 10.1136/Bmj.J3932 on 13 September 2017

    Multivariate and Network Meta-Analysis of Multiple Outcomes BMJ: First Published As 10.1136/Bmj.J3932 on 13 September 2017

  • Cohort Studies and Relative Risks

    Cohort Studies and Relative Risks

  • Alternative Analysis Methods for Time to Event Endpoints Under Non-Proportional

    Alternative Analysis Methods for Time to Event Endpoints Under Non-Proportional

  • Multi-Omics Approach Identifies Novel Pathogen-Derived Prognostic Biomarkers in Patients with Pseudomonas Aeruginosa Bloodstream

    Multi-Omics Approach Identifies Novel Pathogen-Derived Prognostic Biomarkers in Patients with Pseudomonas Aeruginosa Bloodstream

Top View
  • The Hazard Ratio Is Interpretable As an Odds Or a Probability Under the Assumption of Proportional Hazards David M
  • Non-Inferiority Clinical Trials to Establish Effectiveness
  • Estimating Power Calculations and Sample Size
  • Commonly Reported Statistics & Concepts Quick Reference Sheet
  • Non-Constant Hazard Ratios in Randomized Controlled Trials with Composite Endpoints
  • Relative Effect Sizes for Measures of Risk
  • Final Research Report
  • Risk of Mortality in Patients Infected with SARS-Cov-2 Variant of Concern 202012/1: Matched Cohort Study BMJ: First Published As 10.1136/Bmj.N579 on 9 March 2021
  • Virulence and Competitive Ability in an Obligately Killing Parasite
  • Observer Bias in Randomized Clinical Trials with Time-To-Event Outcomes
  • Effectiveness of the Pfizer-Biontech and Oxford-Astrazeneca Vaccines
  • Clinical Trial Design New Investigators May 2017
  • Multivariable Mortality Risk Prediction Using Machine Learning for COVID-19 Patients at Admission
  • Randomized Trials Versus Observational Studies
  • Statistical Methods Programmed in Metaview
  • Meta-Analysis of Hazard Ratios
  • Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical
  • Sequential and Adaptive Analysis with Time-To-Event Endpoints


© 2024 Docslib.org    Feedback